Accrued expenses and other current liabilities

3 Months Ended

Mar. 31, 2025

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31, 2025		December 31, 2024
Rebates, chargebacks and returns	$	59,479	$	110,924
Clinical accruals	35,954		41,448
Employee related expenses	4,654		13,102
Contract manufacturing	7,087		4,764
Interest accruals	1,677		4,205
Commercial services	3,152		2,483
Other accruals	6,338		8,608
	$	118,341	$	185,534

See Note 3. “Revenue” for a breakdown of rebates, chargebacks and returns.

Clinical accruals primarily represent unbilled work undertaken by contract research organizations as part of the advancement of the Company's clinical programs.

As of March 31, 2025, rebates, chargebacks and returns of $61.8 million were recorded in Accrued expenses, non-current, of which $45.9 million were reclassified from Accrued expenses and other current liabilities as of December 31, 2024 as they are no longer required to be paid in the twelve months from the balance sheet date following additional information received in the three months ended March 31, 2025.